#esmo21 highlights on pembrolizumab in fully resected high-risk stage ii melanoma: keynote-716 study
Published 2 years ago • 1.5K plays • Length 2:19Download video MP4
Download video MP3
Similar videos
-
3:18
#esmo21 highlights on combination of pembrolizumab plus chemotherapy in mtnbc: the keynote-355 study
-
3:39
keynote-716: pembrolizumab for patients with high-risk stage ii melanoma
-
3:40
aacr 2023 highlights on advances in the treatment of resected high-risk melanoma with jeffrey weber
-
1:36
results from keynote-716: adjuvant therapy with pembrolizumab in high-risk stage ii melanoma
-
5:01
melanoma highlights from esmo 2021
-
1:08
keynote-716: safety profile and results of pembrolizumab for melanoma
-
0:43
keynote-716: adjuvant pembrolizumab for high-risk melanoma
-
6:52
expert report on novel data in (neo)adjuvant treatment of melanoma from asco 2022
-
8:34
#esmo21 expert video report on melanoma
-
2:17
melanoma highlights from esmo 2021
-
5:54
keynote-716: adjuvant therapy with pembrolizumab for patients with high-risk stage ii melanoma
-
2:22
#esmo22 highlights on neoadj. vs adjuvant pembrolizumab in resected stage iii-iv melanoma:swog s1801
-
3:27
#esmo21 highlights on patterns of relapse in nsclc to atezolizumab vs bsc after adj ct: impower010
-
2:18
keynote-716: longer follow up supports pembrolizumab use in stage iib/iic melanoma
-
3:46
results from the keynote-716: pembrolizumab versus placebo after complete resection of high-risk...
-
2:26
#esmo21 highlights on pembro chemo in 1st-line metastatic cervical cancer: the keynote-826 study
-
1:35
#esmo21 highlights on a phase i of dual raf/mek inhibitor fak inhibitor in ovarian cancer (frame)
-
1:11
highlights for skin cancer at esmo 2021
-
2:45
#esmo21 highlights on mfs analysis from comb. treatments in high-risk adv. prostate cancer: stampede